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to be associated with approximately a 85 90% chance of
SVR. There have also been concerns that RVR may differ
depending on which assay is used. In other words, will using
a very sensitive PCR assay with lower limit of detectability
to approximately 10 IU/mL show the same predictability
as the older assays with a detection limit of 50 IU/mL or
those who use an assay with a limit of 500 IU/mL? Current
evidence seems to suggest that no matter which assay is
used, RVR holds its strong predictive value.
While 24wk in genotype 1 RVR is now accepted and even
recommended in some consensus guidelines, shortening
treatment to 16 in those with RVR and genotypes 2 and
3 remains controversial. The largest study with nearly 1500
patients of genotypes 2 and 3 showed that even those
who achieve RVR would beneﬁt (slightly but signiﬁcantly)
from the full 24wk of treatment compared to only 16 wk.
Further study is needed to better deﬁne those subgroups
with genotype 2 and 3 who may be able to shorten duration
of treatment without compromising the chance of achieving
viral clearance. We also need to study increasing duration
or intensifying treatment in those genotype 2 and 3 patients
who do not achieve RVR (about 1/3 of genotype 2 and 3
patients do not achieve RVR), as their sustained virological
response (SVR) rates are only approximately 50% with 24 wk
of treatment. Finally, we should probably start considering
genotypes 2 and 3 separately rather than lumping together
as a single homogeneous entity. It is clear that they behave
slightly differently in response to treatment.
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Due to sharing the same route of transmission, co-infection
of HIV-HBV or HIV-HCV can occur in some patients.
Co-infection with HBV or HCV accelerates liver disease
progression and increases the risk of liver-related mortality
in HIV-infected patients.
Due to low baseline ALT, high baseline HBVDNA and
decreased HBV-speciﬁc T-cell response in HBV-HIV co-
infected patients, treatment with IFN has low efﬁcacy with
HBeAg loss in 0 20% and less tolerability. IFN treatment
should be considered only in patients with ALT more
than 2 times ULN, HBVDNA less than 7 logs copies/ml
and CD4 count greater than 500 cells/mm3. Anti HBV
agents without effect on HIV such as adefovir dipivoxil or
telbivudine is the treatment of choice for patients who not
require HAART. Lamivudine and tenofovir plus other anti
HIV agent are recommended in patients with CD4 more
than 200 cells/mm3 whom HAART is indicated. In order
to prevent immune reconstitution induced-hepatitis ﬂare,
patients with advanced liver disease and low CD4 count
should be initially treated with lamivudine plus tenofovir
until HBVDNA become undetectable before adding the third
agent of HAART.
Peg-IFN plus ribavirin treatment is the standard treatment
for both HCV mono-infection and HCV-HIV co-infection. As
in mono-infected patients, HCV genotype 2, 3 have better
sustained virological (SVR) than genotype 1 (44 69% vs
11 38% in HIV-coinfected patients treated with Peg/IFN
plus ribavirin). Drug interaction and mitochondrial toxicity
must be carefully monitored through out treatment period
in patient receiving HAART. Didanosine should be avoided
in patients receiving ribavirin. On treatment virological
response have a good predictive of response and may be
used to guide treatment decision.
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Across Europe the incidence of meningococcal disease varies
from between 1 per 100,000 up to 14.3 per 100,000
population per annum. The case fatality rate overall
is approximately 8%, but amongst survivors there is a
relatively high frequency of severe sequelae including
hearing impairment, neuro-cognitive abnormalities, severe
skin and soft tissue abnormalities including loss of limbs,
and renal failure. Physicians and paediatricians who treat
meningococcal disease observe a range of severity from
relatively benign disease to severe physiological disruption
leading to death. In general terms, those who present with
meningitis tend to have a better prognosis, whilst those
who present with severe sepsis syndrome have the worst
prognosis. Study of factors associated with the severity
of meningococcal disease is difﬁcult and confounded by
factors such as the sporadic nature of the disease and
marked differences in access to health systems between
individuals. Many studies have shown that the outcome of
meningococcal disease is associated with the phenotype of
the infecting organism. The odds of death from disease are
highest for certain sequence types, for example ST-11/ET-37
complex and ST-32/ET-5 complex. The precise phenotypes
responsible for the enhanced virulence of these sequence
types has not been precisely deﬁned. The major virulence
determinants of Neisseria meningitidis include the polysialic
capsule, LPS immunotypes, sialylation, and outer membrane
proteins including Opa and Opc. Whilst there is no consistent
segregation of virulence determinants in clonal groups asso-
ciated with the most severe disease, organisms expressing
serogroup C have been associated with fatal outcome.
A number of host factors have been identiﬁed as important in
determining severity of disease. Chief amongst these is age
at presentation, with the worst prognosis being associated
with adults. Some of this may be explained by the increasing
sophistication of paediatric intensive care. Twin studies have
indicated that death from severe infectious disease has a fa-
milial component and in the case of meningococcal disease a
large number of studies have been conducted to investigate
the role of genes encoding components of the immune sys-
tem, the inﬂammatory response and coagulation pathways.
The difﬁculty faced by geneticists is that death is the most
easily veriﬁable end point for the purpose of studying ge-
netic modiﬁers of severity of disease. Because of the death
rate of only 8% this means that very small cohorts are avail-
able for study. However, association studies have revealed a
relationship between a number of genes and the likelihood
of death in meningococcal disease. These include Fc
receptors, polymorphisms of plasminogen activator inhibitor
type 1, properdin deﬁciencies, and polymorphisms within
interleukin 1 and the interleukin 1 receptor antagonist.
In several countries, there have been increasing reporting of
isolates of Neisseria meningitidis with reduced sensitivity to
penicillin. Treatment failure has been reported extremely
rarely and studies have failed to demonstrate any
association between reduced penicillin susceptibility and
fatal outcome. Most doctors consider that emergency
treatment of newly-presenting cases with penicillin in the
community is mandatory. Controversially, a recent study
has suggested that treatment in the home with injected
penicillin may be associated with increased severity of
disease. This will be discussed.
